UBX Jun 2024 2.000 call
| Previous close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.2000 |
| Strike | 2.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.2500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
GlobeNewswireUNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team remains focused on the enrollment and execution of our Phase 2b ASPIRE study in diabetic macular edema, comparing UBX1325 (foselutoclax) against aflibercept," said Anirvan Ghosh, Ph.D., chief executive officer
- GlobeNewswire
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington. ARVO 2024 Presentation Details: Title: Effect of Patient Baseline Characteristics
- GlobeNewswire
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been extended from 24 to 36 weeks to assess potentially greater durability compared to aflibercept. In addition, the study is being upsized from 40 to 50 patients to increase the statistical power. The ASPIRE study is desig
